NCT06992258
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Recruiting
PHASE2Ages 18+InterventionalTreatmentCriterium, Inc.
~120 participants
Updated 2026-03-17 on ClinicalTrials.gov
What's tested:Fruquintinib+ Lonsurf (trifluridine and tipiracil)Fruquintinib
At a glance
Recruiting sites
9 of 9 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To estimate the progression-free survival (PFS) benefit of fruquintinib in combination with TAS-102 as compared to fruquintinib
Measured over 24 months
Conditions
Where it's being run
9 sites across 8 statesFlorida2
Connecticut1
New Jersey1
New York1
Pennsylvania1
Tennessee1
Texas1
Virginia1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To estimate the progression-free survival (PFS) benefit of fruquintinib in combination with TAS-102 as compared to fruquintinib24 months
Progression free survival (PFS) defined as time from randomization to first observation of progression using RECIST v1.1 or death from any cause.